Navigation Links
Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
Date:10/6/2011

tuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

The many clinical trials conducted in the field of active immunotherapy of cancer over the last decade have provided increasing evidence that it is possible to engage the immune system to focus on and destroy cancer cells. Part of what has been learned over this time is the importance of specific activation of CD4+ T-helper cells in the generation of a robust and effective immune response. Equally clear is the validity of the HER2 protein as a target for cancer therapy. Importantly, HER2 is expressed at low to intermediate levels in a high percentage of breast as well as many other tumor types.  HER2 expression at these levels requires active immunotherapy, such as AE37, rather than passive immunotherapy such as Herceptin. For this reason, the company is continuing with plans for a Phase II prostate cancer study as well as other novel clinical applications of AE37 with interested parties.

"Antigen Express continues to make progress
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antigen Express AE37 Cancer Vaccine Featured in Scientific American
2. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
3. Generex Provides Update on Spinout of Antigen Express
4. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
5. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
8. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
9. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
10. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
11. Medicago succesfully expresses VLP antigen for A H1N1 strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Markets Inc. (OTCQX: PINK), the financial information and ... quotation and trading system in the U.S. OTC ... (OTCQX: CRMMF, TSX.V: CRM), a Canadian-based medical technology ... highest tier, OTCQX®. (Logo:   http://photos.prnewswire.com/prnh/20090708/NY43125LOGO ...
... DIEGO, Aug. 17 MabVax Therapeutics, Inc., a privately ... of vaccine and antibody based therapies to address the ... it has received a Small Business Innovation Research Grant ... agency,s Streamlined Non-competing Award Procedures (SNAP). Under the SNAP ...
... of only two studies of its kind, a study from ... School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral ... eye disease and preserve vision. The team developed nanoparticles to ... mice temporarily retained more eyesight than controls. The study, published ...
Cached Biology Technology:CRH Medical Corp. Joins OTCQX 2CRH Medical Corp. Joins OTCQX 3MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 2MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 3Breakthrough gene therapy prevents retinal degeneration 2
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be ... Acuity Market Intelligence reports that the long anticipated ... Acuity forecasts that intensifying demand for smart phones, ... will drive a global market of 2.5 billion ... 2020.   According to Maxine ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... A new paper published online in Nature ... type of lung cancer may one day benefit from targeted ... Squamous cell lung cancer kills more people each ... to lung adenocarcinoma in the number of deaths it causes. ...
... extensive forest death triggered by hot and dry climatic ... Forest mortality due to drought and heat stress is ... has focused on isolated incidents of forest mortality, little ... die-offs. A new analysis of the current literature on ...
... applied fertilizer to newly placed sod may result in nutrient ... best time to apply fertilizer and what kind is the ... is a team of scientists from Texas A&M AgriLife Research: ... management; Dr. Ben Wherley, assistant professor of turfgrass science and ...
Cached Biology News:New potential targets discovered for treating squamous cell lung cancers 2New potential targets discovered for treating squamous cell lung cancers 3Forest mortality and climate change: The big picture 2Forest mortality and climate change: The big picture 3Turf study to monitor runoff, establish fertilizer management practices 2
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
... Mass Standards Kit includes reagents that can ... instrument parameters, and calibrate the mass scale ... designed for use with the 4700 Proteomics ... Standards in the kit require minimal preparation ...
...
Biology Products: